公开(公告)号：US20200282056A1

公开(公告)日：2020-09-10

申请号：US16074707

申请日：2017-02-02

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61N5/06 ,  A61N5/10

摘要： A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

公开(公告)号：US20170113061A1

公开(公告)日：2017-04-27

申请号：US15318906

申请日：2015-06-18

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Eric J. TOONE ,  David GOODEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER

IPC分类号： A61N5/06 ,  A61K39/00 ,  A61N5/10 ,  C07D493/04

CPC分类号： A61N5/062 ,  A61K39/39 ,  A61N5/0601 ,  A61N5/0616 ,  A61N2005/0612 ,  A61N2005/063 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  C07D493/04

摘要： Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an auto vaccine effect in a subject using the method.

公开(公告)号：US20240342287A1

公开(公告)日：2024-10-17

申请号：US18751743

申请日：2024-06-24

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61K45/06 ,  A61N5/06 ,  A61N5/10

CPC分类号： A61K41/0066 ,  A61K31/37 ,  A61N5/062 ,  A61N5/10 ,  A61K45/06 ,  A61N2005/0661 ,  A61N2005/1098

摘要： A kit for use in performing a cancer treatment, having a vial containing a phosphor-containing drug activator, wherein the phosphor-containing drug activator is present in the vial at a dosage level that is correlated with a size of tumor to be treated, and a container containing the vial;



wherein the phosphor-containing drug activator contains an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; where the two or more phosphors include Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating and a diamond-like carbon coating.

公开(公告)号：US20200222711A1

公开(公告)日：2020-07-16

申请号：US16728803

申请日：2019-12-27

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. Bourke, JR. ,  Zakaryae Fathi ,  Wayne F. Beyer, JR. ,  Mark Dewhirst ,  Mark Oldham ,  Justus Adamson ,  Michael Nolan

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US20200078600A1

公开(公告)日：2020-03-12

申请号：US16516463

申请日：2019-07-19

申请人： Immunolight, LLC. ,  Duke University

发明人： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC分类号： A61N5/06 ,  A61K49/00 ,  A61N1/40 ,  A61N5/02 ,  A61B5/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61L2/00

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20190336786A1

公开(公告)日：2019-11-07

申请号：US16511605

申请日：2019-07-15

申请人： Immunolight, LLC. ,  Duke University

发明人： Frederic A. BOURKE, JR. ,  Tuan VO-DINH ,  Harold WALDER

IPC分类号： A61N5/06 ,  A61K41/00 ,  A61N5/02 ,  A61N5/10 ,  A61K47/69

摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US20150202294A1

公开(公告)日：2015-07-23

申请号：US14603539

申请日：2015-01-23

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Wenle XIA ,  David GOODEN ,  Erik J. SODERBLOM ,  Eric J. TOONE ,  Neil L. SPECTOR ,  Wayne F. BEYER, JR. ,  Harold WALDER

IPC分类号： A61K41/00 ,  A61K51/12 ,  A61K31/37 ,  A61K31/4709 ,  A61K31/436 ,  A61K31/517

CPC分类号： A61K31/436 ,  A61K31/37 ,  A61K31/4709 ,  A61K31/517 ,  A61K41/0066 ,  A61K45/06 ,  A61K2300/00

摘要： Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.

摘要翻译： 用于治疗受试者细胞增殖疾病或病症的方法，包括将缺乏DNA交联基序的补骨脂素衍生物施用于癌细胞，施用补骨脂素或其衍生物和拉帕替尼，或施用补骨脂素或其衍生物和神经胶质细胞 ，并且进一步施加起始辐射能量形成能量源。

公开(公告)号：US20200009398A1

公开(公告)日：2020-01-09

申请号：US16554831

申请日：2019-08-29

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Mark OLDHAM ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Mark DEWHIRST ,  Neil L. SPECTOR ,  Paul YOON ,  Justus ADAMSON ,  David ALCORTA ,  Kim LYERLY ,  Leihua LIU ,  Takuya OSADA

IPC分类号： A61N5/06 ,  A61K31/352 ,  A61K41/00

摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

公开(公告)号：US20190184190A1

公开(公告)日：2019-06-20

申请号：US16322178

申请日：2017-08-01

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE ,  Zakaryae FATHI ,  Wayne BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Paul YOON

IPC分类号： A61N5/06 ,  A61N5/10 ,  A61P35/00 ,  A61K41/00

CPC分类号： A61N5/062 ,  A61K33/42 ,  A61K41/00 ,  A61K41/0057 ,  A61N5/10 ,  A61N2005/1098 ,  A61P35/00

摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

公开(公告)号：US20180311355A1

公开(公告)日：2018-11-01

申请号：US15770926

申请日：2016-10-26

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

发明人： Mark OLDHAM ,  Justus ADAMSON ,  Mark W. DEWHIRST ,  Paul YOON ,  Harold WALDER ,  Frederic A. BOURKE ,  Zakaryae FATHI ,  Wayne F. BEYER

IPC分类号： A61K41/00 ,  A61N5/06 ,  A61K33/24 ,  A61N5/10

CPC分类号： A61K31/655 ,  A61K31/352 ,  A61K31/403 ,  A61K31/409 ,  A61K31/525 ,  A61K33/02 ,  A61K41/0066 ,  A61N5/062 ,  A61N5/0624 ,  A61N2005/065 ,  A61N2005/1095 ,  A61N2005/1098 ,  Y02A50/393

摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.